Results per Page:
All eyes on IL-6 when it comes to CMV reactivation after bone marrow transplantation
From the Hill Lab in Translational Sciences and Therapuetics Division
Investigating CMV reactivation in CARTx patients reveals high risk patients
From the Hill lab, Vaccine and Infectious Disease, Clinical Research and Translational Sciences and Therapeutics Divisions
CMV breakthrough and resistance to antiviral drug after blood stem cell transplants
From Dr. Danniel Zamora and the Boeckh Group, Vaccine and Infectious Disease Division
Naïve and memory T cells elicit a convergent response to CMV
From the Boeckh, Bradley, and Prlic Labs, a collaboration between the Vaccine and Infectious Disease, Clinical Research, and Public Health Sciences Divisions
A lasting impression: CMV exposure imprints donor T cell phenotypes
From the Hill Lab, Clinical Research Division
Infectious Diseases Society to honor Dr. Michael Boeckh
Hutch virus expert to deliver John F. Enders Lecture at Washington, D.C., conference
Rethinking an old viral foe
Why does a common virus plague bone marrow transplant patients? New study challenges dogma, opens door to new therapies.
With approval of new CMV drug for transplant patients, a legacy continues
Tissue samples from a clinical trial conducted decades ago yield new insights and treatments
Adam Geballe elected AAAS Fellow
Hutch virologist honored for revealing key players in molecular ‘arms race’ between viruses and hosts
Drs. Colleen Delaney, Harlan Robins named 2016 Leaders in Health Care
Celebrating faculty and staff achievements